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Hepatic resection together with perioperative chemotherapy 
is currently the only treatment option that can offer a 
chance of long-term outcome in patients with colorectal 
liver metastases (CRLM), resulting in 5-year survival rates 
of 40%, and exceeding 50% in selected patients (1,2).
The safety of liver resections in high-volume centers 
and the increased efficacy of perioperative chemotherapy 
regimens have improved and expanded the indications 
to surgery for CRLM (3). Patients with advanced disease 
(extensive multinodular and bilateral CRLM), often 
classified as unresectable at the time of diagnosis have 
the possibility to undergo curative liver resection after 
downstaging by conversion chemotherapy (4,5). In such 
patients, the multilocularity and bilaterality of the disease 
may represent a technical issue for liver resection because 
of the inability to achieve radical resection while preserving 
sufficient functional liver volume.
Surgical management for patients with advanced bilateral 
CRLM includes three main strategies: the two-stage 
hepatectomy (TSH), initially described by Adam et al. in 
2000 (6), the enhanced one-stage parenchymal-sparing 
hepatectomy, described by Torzilli et al. (7), and the associating 
liver partition and portal vein ligation for staged hepatectomy 
(ALPPS) procedure described by Schnitzbauer et al. (8).
By the use of these surgical techniques, an increasing 
number of patients with advanced bilobar CRLM have 
undergone curative surgical resection with 5-year overall 
survival rates similar to those following resections for 
unilobar disease (9).
However, despite the recent improved overall survival of 
patients resected for CRLM, recurrence still represents the 
critical oncological issue. Indeed about 60–70% of resected 
patients will recur and more than 50% of patients will 
develop recurrence within 2 years after liver resection (10). 
Of course, the risk of liver recurrence following aggressive 
procedures such as TSH, enhanced one-stage hepatectomy 
and ALPPS, is reported to be higher because of the more 
extensive disease in such patients. Indeed, the rate of 
recurrence following TSH is reported to be >70% (11,12).
It has been largely shown that repeat hepatectomy for 
liver recurrence is safe and effective in selected patients (13). 
Indeed, repeat hepatectomy may increase the chance of 
long-term survival for patients with recurrence in the liver, 
with reported 5-year survival rates ranging from 30% 
to 60%. These survival rates are comparable to those of 
patients who only underwent single hepatectomy.
Because of the high risk of liver recurrence following 
liver resection for CRLM, the first liver resection should 
always be performed taking into account the possibility 
of repeat hepatectomy. For these reasons, in patients with 
multiple bilobar metastases, if complete resection is possible, 
the one-stage parenchymal-sparing hepatectomy should 
be favoured and should be considered as the gold-standard 
technique in patients with CRLM. Indeed, it has been 
reported that the parenchymal-sparing procedure, rather 
than a major hepatectomy, may increase the possibility of 
repeat hepatectomy in case of liver recurrence. However, in 
selected patients, TSH may be indicated. Indications for TSH 
include patients with multiple and bilateral CRLM in whom 
complete removal of all metastases is not feasible by a single 
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hepatectomy because of insufficient future remnant liver.
Several studies have focused on the possibility of 
repeat hepatectomy in selected patients, also after major 
hepatectomy, and on the impact on overall survival. The 
rate of repeat hepatectomy may vary according to the 
expertise and to the surgical policy of the Center. The 
reported rates of repeat hepatectomy range from 8% to 
35% (14). A recent Eastern paper by Takamoto et al. (14) 
reported a high rate of repeat hepatectomy (50% for all 
recurrences and 87% for liver only recurrences).
However, few studies evaluated the management of 
patients with liver recurrence following TSH (12,15). A 
recent interesting paper by Imai et al. (15) analyzed the 
results of repeat surgery in one of the largest series of 
TSH for CRLM. In this study, among 139 patients with 
advanced bilateral CRLM scheduled for TSH between 
1992 and 2012, 93 completed the TSH program and finally, 
a potentially curative surgery with resection of extrahepatic 
disease and of the primary tumor was achieved in 81 
patients. Rate of recurrence in such patients was 76.5% (62 
patients). The overall rate of repeat surgery was 53.2% and 
reached 60.4% in patients with single-site recurrence. 
The 5-year overall survival rate in patients who 
completed the TSH was 41.3%. This result was similar to 
that published in other series (11,12) and confirmed that 
the TSH strategy may add a survival benefit in selected 
patients. Recurrence rate in such patients was high (76.5%) 
and the 5-year disease-free survival rate was low (8.9%), 
however the 5-year overall survival rate was similar to that 
following single liver resection (41.3%). These results may 
be explained by the high rate of repeat surgery performed 
in this series (53%), which had a significant impact on 
the long-term outcome of such patients. Indeed, the 
study showed that patients who underwent repeat surgery 
presented a significantly higher overall survival than those 
who did not. Moreover, at multivariate analysis, repeat 
surgery was an independent favorable prognostic factor. The 
authors showed that, although the disease-free survival was 
short (the time interval between second-stage hepatectomy 
and the first recurrence), the secondary disease-free survival 
(the time interval between second-stage hepatectomy and 
the first recurrence that could not be curatively treated) was 
longer, confirming the impact and benefit of repeat surgery.
The crucial issue analyzed in the study by Imai et al. (15) 
is the possibility of repeat liver resection following extended 
hepatectomy. Generally, repeat liver resection following 
major hepatectomy may be more difficult and less frequent. 
In the Eastern paper by Takamoto et al. (14) it has been 
showed that repeat liver resection was feasible and safe even 
if major hepatectomy was initially performed. Moreover, 
the type of first liver resection did not have any significant 
impact on the overall survival after repeat hepatectomy. 
Indeed, no significant difference in overall survival was 
found between patients who received repeat hepatectomy 
after major hepatectomy and those after minor hepatectomy.
The paper by Imai et al. (15) demonstrated that repeat 
hepatectomy was feasible even after one of the most 
aggressive approach such as TSH. The Paul Brousse 
experience (15), together with that from the MD Anderson 
Cancer Center (12), showed the results of the largest 
surgical series of TSH. The rates of repeat surgery 
following TSH in these two Centers were 53.2% and 37%, 
respectively, comparable to those reported in other surgical 
series following minor liver resections. In other words, 
repeat hepatectomy shows a fundamental impact on long-
term outcome in patients with recurrent CRLM and, as 
demonstrated for major hepatectomies by Prof. Makuuchi’s 
series (14) and for TSH by Prof. Adam’s series (15), the type 
of the first liver resection was not always correlated with 
the possibility of re-resection. The paper by Imai et al. (15) 
highlights that the possibility of repeat hepatectomy is 
strongly correlated with the aggressiveness of surgical 
management, which could be different according to the 
expertise and the policy of each Center.
Finally, as suggested in the paper by Imai et al. (15), this 
aggressive surgical management of recurrent disease may be 
applied also in patients with recurrence following ALPPS.
In conclusions, in case of extensive multiple bilateral 
CRLM, all the possible strategies (TSH, one-stage 
parenchymal-sparing hepatectomy and ALLPS) should 
be evaluated and accurately tailored to each patient. We 
do not have yet enough definitive data to classify one 
technique oncologically superior to each other. It should 
be highlighted that indication to perform TSH will not 
preclude the possibility of repeat hepatectomy. For these 
reasons, the choice should be based on the characteristics of 
the disease, of the patient and of the liver parenchyma, and 
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